Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing Deep Cyclic Inhibitors, with a lead focus on atebimetinib, an oral, once-daily MEK inhibitor for MAPK pathway-driven cancers such as pancreatic cancer. This news page aggregates company announcements, clinical data updates, financing news, and other disclosures that Immuneering releases through press statements and regulatory filings.
Readers can find detailed coverage of Immuneering’s clinical trial progress, including Phase 2a data for first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP). The company has reported updated overall survival, progression-free survival, response rates, and safety findings from a cohort of 34 patients, as well as case studies of patients treated with atebimetinib plus FOLFIRINOX. Immuneering also provides timelines for anticipated milestones such as additional survival data readouts and the planned initiation of a global Phase 3 registrational trial in metastatic pancreatic cancer.
In addition to clinical results, Immuneering’s news flow includes corporate and financial updates such as quarterly financial results, underwritten public offerings of Class A common stock, private placements with institutional investors, and guidance on expected cash runway. Announcements related to index inclusion, such as the company’s expected addition to the Nasdaq Biotechnology Index, and conference presentations at healthcare and scientific meetings are also part of the regular news cycle.
Investors and followers of oncology drug development can use this page to track Immuneering’s disclosures about regulatory interactions with the FDA and EMA, combination trial agreements in non-small cell lung cancer, and intellectual property developments such as the granting of a U.S. composition of matter patent for atebimetinib. Bookmark this feed to monitor how Immuneering’s Deep Cyclic Inhibitor programs and corporate strategy evolve through official company communications.
Immuneering Corporation (Nasdaq: IMRX) has reported promising preclinical data for IMM-6-415, aimed at treating RAF and RAS mutant tumors. The data, presented at the SITC 37th Annual Meeting, shows that IMM-6-415 can operate effectively as a monotherapy and enhance the activity of immune checkpoint inhibitors. It demonstrates a uniquely short half-life, offering an accelerated dosing cadence compared to IMM-1-104. The company anticipates submitting an IND for IMM-6-415 in Q4 2023, with early studies indicating a significant therapeutic potential against hard-to-treat solid tumors.
Immuneering Corporation (Nasdaq: IMRX) has commenced recruiting for a Phase 1/2a clinical trial of IMM-1-104, targeting advanced solid tumors with RAS mutations. The first patient is expected to be dosed this quarter. Additionally, promising preclinical data on its second drug, IMM-6-415, was presented at the SITC meeting. Financially, the company reported cash and equivalents of $117.2 million, expected to last into Q3 2024. However, R&D expenses grew to $9.4 million from $6.2 million year-over-year, contributing to a net loss of $12.8 million for Q3 2022.
Immuneering Corporation (Nasdaq: IMRX) announced participation in three investor conferences in November 2022 to discuss its pipeline and business strategy. CEO Ben Zeskind and CSO Brett Hall will present at the Jefferies London Healthcare Conference on November 15, the Piper Sandler Healthcare Conference on November 29, and the Evercore ISI HealthCONx Conference on December 1. The company is advancing its lead candidate, IMM-1-104, currently in a Phase 1/2a trial for tumors with RAS mutations, aiming for targeted cancer treatment.
Immuneering Corporation (Nasdaq: IMRX) has appointed Leah R. Neufeld as Chief People Officer, a newly created position, effective immediately. Neufeld brings extensive experience from her previous roles at Luzsana Biotechnology and Prevail Therapeutics. CEO Ben Zeskind emphasized her leadership skills and expertise in enhancing company culture and attracting top talent. Immuneering focuses on developing medicines for patients with solid tumors driven by RAS mutations and MAPK pathway activations, leveraging its proprietary bioinformatics platform.
Immuneering Corporation (Nasdaq: IMRX) announced it will present data on its second program, IMM-6-415, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 8-12, 2022, in Boston. The poster presentation, titled Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, highlights its potential in enhancing PD1 and CTLA4 checkpoint blockade for RAS mutant tumors. IMM-6-415 is a third-generation dual MEK inhibitor aimed at improving cancer therapies for patients with solid tumors driven by RAS mutations.
Immuneering Corporation (Nasdaq: IMRX) has received FDA clearance for its Investigational New Drug (IND) application for IMM-1-104, enabling the initiation of a Phase 1/2a clinical trial targeting advanced RAS mutant solid tumors. The trial, anticipated to start in Q4 2022, aims to evaluate the safety, tolerability, and preliminary anti-cancer activity of this novel drug. This trial is notable for including patients with any RAS mutation, marking a significant step towards expanding treatment options for cancer patients with solid tumors driven by RAS mutations.
Pyramid Biosciences has expanded its leadership team by appointing Biren Amin as Chief Financial and Strategy Officer. Amin, previously CFO at Immuneering Corporation (NASDAQ: IMRX), brings over two decades of experience in oncology and biotechnology. The company is focused on developing precision therapies for cancer, particularly with its lead program PBI-200, a TRK inhibitor for NTRK fusion-driven cancers. The CEO expressed confidence in Amin's expertise to guide corporate strategy and advance the product pipeline during a period of significant growth for the company.
Immuneering Corporation (Nasdaq: IMRX) has submitted an Investigational New Drug (IND) application to the FDA for its oral small molecule, IMM-1-104, aimed at treating advanced RAS mutant solid tumors. This third generation MEK inhibitor is designed for broad pan-RAS activity and has shown robust anti-tumor effects in preclinical models, including KRAS mutant cancers. The company plans to initiate a Phase 1/2a clinical trial, with expectations to enroll the first patient in Q4 2022, pending regulatory approval.
Immuneering Corporation (Nasdaq: IMRX) will participate in two investor conferences in September 2022, focusing on its drug pipeline and business strategy. CEO Ben Zeskind and CSO Brett Hall will represent the company. Key dates include the Wells Fargo Healthcare Conference on September 8 in Boston and the Morgan Stanley Global Healthcare Conference on September 14 in New York, featuring a fireside chat at 2:05 pm ET. Immuneering aims to enhance cancer treatment through its innovative pipeline, including the lead candidate IMM-1-104, targeting advanced solid tumors.
Immuneering Corporation (NASDAQ: IMRX) announced its financial results for Q2 2022, reporting a net loss of $11.5 million, or $0.44 per share, up from $8.0 million, or $1.61 per share, in Q2 2021. The company holds $128.1 million in cash and equivalents, sufficient to fund operations until Q3 2024. Upcoming milestones include filing an IND for IMM-1-104, targeting RAS mutation-driven tumors, this quarter, and the first patient enrollment in Q4 2022. Additionally, an IND for IMM-6-415 is expected in 2023.